Diagnosing the decline in pharmaceutical R&D efficiency
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (RD). Yet the number of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining RD efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For over fifty years, the pharmaceutical industry has seen the cost of developing drugs increase exponentially from tens of millions in the 1950s to billions of dollars today, even when the data is adjusted for inflation [1].”
From Drug design on quantum computers (2024) · doi:10.1038/s41567-024-02411-5 · cites this paper as [1]
Citations
Cites
Collective dynamics of ‘small-world’ networks
Watts, D. J., & Strogatz, S. H. (1998) · Nature · doi:10.1038/30918 · Cited by 43,060
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“It is hard to look at the genesis of drugs like crizotini”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“First, estimates of the number of potential drug target”
Background
Research works printed but not linked: 6
- Ruffolo, R. R. Engineering success: Wyeth redefines its research & development organisation. Drug Discovery World website [online] , (2005).
- Young, M. P. Prediction v Attrition. Drug Discovery World website [online] , (2008).
- Healy, D. The Psychopharmacologists: Volume 2 93–118 (Hodder Arnold, London, 1999).
- Healy, D. The Psychopharmacologists: Volume 2 259–264 (Hodder Arnold, London, 1999).
- Mathieu, M. P. (ed.) Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2010/2011 163–261 (Barnett International, Needham, Massachusetts, 2010).
- Munos, B. How to avert biopharma's R&D crisis. In Vivo 29, 2011800050 (2011).
Cited by
Items 301–400 of 1,002
Social Learning of Prescribing Behavior Can Promote Population Optimum of Antibiotic Use
Chen, X., & Fu, F. (2018) · Frontiers in Physics · doi:10.3389/fphy.2018.00139 · Cited by 64
“Food and Drug Administration (FDA) has been dramatically reduced, suggesting an “EROOM” law (a phenomenon in contrast to the Moore’s law) [11, 20, 21].”
BackgroundApplications of artificial intelligence in drug delivery and pharmaceutical development
Colombo, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818438-7.00004-6 · Cited by 62
Web-based drug repurposing tools: a survey
Sam, E., & Athri, P. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx125 · Cited by 69
Deep Learning for Drug Discovery and Cancer Research: Automated Analysis of Vascularization Images
Urban, G., Bache, K., Phan, D. T. T., Sobrino, A., Shmakov, A., Hachey, S. J., Hughes, C. C. W., & Baldi, P. (2018) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2018.2841396 · Cited by 63
“has exhibited a steady, exponential rise over the past five decades [1].”
Olk, P. M., & West, J. (2019) · R and D Management · doi:10.1111/radm.12364 · Cited by 70
“One major reason is what Scannell et al. (2012) term the ‘Better than the Beatles’ dilemma, as new drugs must compete with former blockbusters that are now off-patent and available at commodity generic prices.”
Drug-pathway association prediction: from experimental results to computational models
Wang, C.-C., Zhao, Y., & Chen, X. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa061 · Cited by 66
Niazi, S. K. (2025) · Pharmaceuticals · doi:10.3390/ph18091271 · Cited by 61
“This timeline illustrates how computational power, algorithm sophistication, and data availability have created an increasingly diverse toolkit for small-molecule discovery rather than a single dominant methodology [13,20] (Figure 1).”
Hirano, T., Motohashi, T., Okumura, K., Takajo, K., Kuroki, T., Ichikawa, D., Matsuoka, Y., Ochi, E., & Ueno, T. (2020) · Journal of Medical Internet Research · doi:10.2196/18938 · Cited by 68
“As the complexity and size of clinical trials grow, it has become increasingly expensive to apply the 100% SDV approach [2,3].”
MethodSex differences in the neurochemistry of frontal cortex: Impact of early life stress
Perry, C. J., Campbell, E. J., Drummond, K. D., Lum, J. S., & Kim, J. H. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15208 · Cited by 64
“Some psychiatric conditions such as stimulant use disorder have no pharmacotherapeutics available, and the discovery rate of novel pharmacotherapy is almost at a standstill for psychiatry (Scannell et al., 2012).”
BackgroundNegative modulation of mitochondrial calcium uniporter complex protects neurons against ferroptosis
Marmolejo-Garza, A., Krabbendam, I. E., Luu, M. D. A., Brouwer, F., Trombetta-Lima, M., Unal, O., O’Connor, S. J., Majerníková, N., Elzinga, C. R. S., Mammucari, C., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06290-1 · Cited by 70
The applications and advances of artificial intelligence in drug regulation: A global perspective
Lixia, F., Jia, G., Liu, Z., Pang, X., & Cui, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.11.006 · Cited by 61
“However, drug research and development (R&D) remains a time-consuming and costly process, with efficiency declining around 80-fold since 1950, beset by various factors such as high failure rates and uncertainty 6,7 .”
Leung, D., Lamberto, D. J., Liu, L., Kwong, E. C., Nelson, T. D., Rhodes, T. A., & Bak, A. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.05.003 · Cited by 61
Engineering in vitro models of hepatofibrogenesis
Mazza, G., Al‐Akkad, W., & Rombouts, K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.018 · Cited by 65
Thavaneswaran, S., Sebastian, L. T., Ballinger, M. L., Best, M. C., Hess, D., Lee, C. K., Sjoquist, K. M., Hague, W. E., Butow, P. N., Simes, R. J., et al. (2018) · The Medical Journal of Australia · doi:10.5694/mja18.00227 · Cited by 61
Tagle, D. A. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.09.007 · Cited by 68
Ghosh, J., Lawless, M. S., Waldman, M., Gombar, V. K., & Fraczkiewicz, R. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3609-0_4 · Cited by 61
“Nat Rev Drug Discov 11(3):191–200, 2012).”
BackgroundOrgans on microfluidic chips: A mini review
Jiang, B., Zheng, W., Zhang, W., & Jiang, X. (2013) · Science China Chemistry · doi:10.1007/s11426-013-4971-0 · Cited by 62
Yang, J., Kwon, S., Bae, S.-H., Park, K. M., Yoon, C., Lee, J., & Seok, C. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00104 · Cited by 61
Drug Repurposing Approaches to Combating Viral Infections
Trivedi, J. S., Mohan, M., & Byrareddy, S. N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113777 · Cited by 62
“Despite enormous advances in pharmaceutical technologies and our understanding of disease transmission and pathogenesis, the failure rates of drugs have amplified in the past few decades [23,24].”
BackgroundSmart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport
Elz, A. S., Trevaskis, N. L., Porter, C. J. H., Bowen, J. M., & Prestidge, C. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.003 · Cited by 64
Use of the conditional marketing authorization pathway for oncology medicines in Europe
Hoekman, J., Boon, W., Bouvy, J. C., Ebbers, H. C., de Jong, J., & Bruin, M. L. D. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.174 · Cited by 60
“expressed concerns about an increasingly risk-averse regulatory environment and rising costs of drug development.(4) In 2006, conditional marketing authorization (CMA) was introduced in the European Union (EU) as an early access pathway for medicines that fulfill an unmet medical need and treat seriously debilitating,…”
BackgroundLandeck, L., Kneip, C., Reischl, J., & Asadullah, K. (2016) · Experimental Dermatology · doi:10.1111/exd.12948 · Cited by 67
“The number of FDA approved drugs per billion US dollars of spending has halved approximately every nine years.(61) Regular costs to launch a new drug exceeds > 1 billion € and raises concerns.”
BackgroundThe emerging role of computational design in peptide macrocycle drug discovery
Mulligan, V. K. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1751117 · Cited by 58
“Despite major scientific advancements to the drug development process, and rising investment of person-hours, money, and resources, the number of new molecular entities approved for clinical use each year has remained steady [3,4], meaning that the cost of introducing a new drug is rising [5].”
BackgroundR&D efficiency of leading pharmaceutical companies – A 20-year analysis
Schuhmacher, A., Wilisch, L., Kuss, M., Kandelbauer, A., Hinder, M., & Gassmann, O. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.05.005 · Cited by 71
Timelines of translational science: From technology initiation to FDA approval
McNamee, L. M., Walsh, M. J., & Ledley, F. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177371 · Cited by 59
“The problem is well documented; the annual number of approvals of New Molecular Entities (NMEs) has been static [1], clinical development pipelines continue to have high attrition rates [2], and drug development costs are increasing exponentially [3].”
BackgroundBenchmarking network propagation methods for disease gene identification
Picart‐Armada, S., Barrett, S. J., Willé, D. R., Perera-Lluna, A., Gutteridge, A., & Dessailly, B. H. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007276 · Cited by 66
“The pharmaceutical industry faces considerable challenges in the efficiency of commercial drug research and development [1] and in particular in improving its ability to identify future successful drug targets.”
Background1- and 2-Azetines via Visible Light-Mediated [2 + 2]-Cycloadditions of Alkynes and Oximes
Wearing, E. R., Blackmun, D. E., Becker, M., & Schindler, C. S. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c07523 · Cited by 59
Machine Learning with Statistical Imputation for Predicting Drug Approval
Lo, A. W., Siah, K. W., & Wong, C. H. (2019) · Harvard Data Science Review · doi:10.1162/99608f92.5c5f0525 · Cited by 59
Capitalizing a Cure: How Finance Controls the Price and Value of Medicines
Roy, V. (2023) · University of California Press eBooks · doi:10.1525/9780520388727 · Cited by 66
Grand Challenge of Quantum Applications
Babbush, R., King, R., Boixo, S., Huggins, W. J., Khattar, T., Low, G. H., McClean, J. R., O’Brien, T. E., & Rubin, N. C. (2026) · PRX Quantum · doi:10.1103/6r9l-lynr · Cited by 70
“In drug discovery, for instance, the primary bottleneck is not generating candidate molecules but assessing their efficacy and toxicity within the complex environment of the human body, a challenge currently solvable only by expensive, high-attrition clinical trials [130].”
Cheng, F., Zhao, J., Fooksa, M., & Zhao, Z. (2016) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocw007 · Cited by 62
“However, the number of new United States Food and Drug Administration (US FDA) approved drugs has nearly halved since 1950, and the cost of drug discovery and development has grown fairly steadily.(1) On the other hand, massive amounts of drug and biological data have been released to the community.”
BackgroundBalasegaram, M., Kolb, P., McKew, J. C., Menon, J., Olliaro, P., Sablinski, T., Thomas, Z., Todd, M. H., Torreele, E., & Wilbanks, J. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002276 · Cited by 56
Sano, E., Mori, C., Matsuoka, N., Ozaki, Y., Yagi, K., Wada, A., Tashima, K., Yamasaki, S., Tanabe, K., Yano, K., et al. (2019) · Micromachines · doi:10.3390/mi10110793 · Cited by 57
Turmeric (Curcuma longa L.): Chemical Components and Their Effective Clinical Applications
Vo, T. S., Vo, T. T. B. C., Vo, T. T. T. N., & LAİ, T. N. H. (2021) · Journal of the Turkish Chemical Society Section A Chemistry · doi:10.18596/jotcsa.913136 · Cited by 71
Mechanistic Basis for the Role of Phytochemicals in Inflammation-Associated Chronic Diseases
Cote, B., Elbarbry, F., Bui, F. Q., Su, J. W., Seo, K., Nguyen, A., Lee, M., & Rao, D. A. (2022) · Molecules · doi:10.3390/molecules27030781 · Cited by 59
Fernald, K., Förster, P. C., Claassen, E., & van de Burgwal, L. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104160 · Cited by 65
Trends in Modern Drug Discovery
Eder, J., & Herrling, P. L. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_20 · Cited by 56
Olsen, R. H., Bihlet, A. R., Kalakou, F., & Andersen, J. R. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-2004-y · Cited by 63
Precision medicine review: rare driver mutations and their biophysical classification
Nussinov, R., Jang, H., Tsai, C., & Cheng, F. (2019) · Biophysical Reviews · doi:10.1007/s12551-018-0496-2 · Cited by 57
Structure-based drug repositioning: Potential and limits
Adasme, M. F., Parisi, D., Sveshnikova, A. N., & Schroeder, M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.010 · Cited by 58
Repositioning of Anthelmintic Drugs for the Treatment of Cancers of the Digestive System
Laudisi, F., Marônek, M., Grazia, A. D., Monteleone, G., & Stolfi, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144957 · Cited by 62
Competition and R&D Financing: Evidence From the Biopharmaceutical Industry
Thakor, R. T., & Lo, A. W. (2021) · Journal of Financial and Quantitative Analysis · doi:10.1017/s0022109021000284 · Cited by 64
“Wedothistoensureparalleltrendsholdbetweenourtreatmentandcontrolgroups, given the documented pre-trends related to innovative output for the biopharma industry (e.g., Scannell et al. (2012)).”
Shafagh, R. Z., Youhanna, S. C., Keulen, J., Shen, J. X., Taebnia, N., Preiss, L. C., Klein, K., Büttner, F., Bergqvist, M., van der Wijngaart, W., et al. (2022) · Advanced Science · doi:10.1002/advs.202203368 · Cited by 60
Chemical representation learning for toxicity prediction
Born, J., Markert, G., Janakarajan, N., Kimber, T. B., Volkamer, A., Martínez, M. R., & Manica, M. (2023) · Digital Discovery · doi:10.1039/d2dd00099g · Cited by 63
Dermawan, D., & Alotaiq, N. (2025) · Pharmaceuticals · doi:10.3390/ph18070981 · Cited by 63
“Key bottlenecks include the inefficient identification of druggable targets, the costly and time-consuming high-throughput screening (HTS) of large chemical libraries, suboptimal lead optimization, and poorly designed clinical trials that fail to stratify patient populations adequately [6].”
Comparative In Vitro Immune Stimulation Analysis of Primary Human B Cells and B Cell Lines
Belle, K. V., Herman, J., Boon, L., Waer, M., Sprangers, B., & Louat, T. (2016) · Journal of Immunology Research · doi:10.1155/2016/5281823 · Cited by 63
In silico drug repositioning: from large-scale transcriptome data to therapeutics
Kwon, O., Kim, W., Cha, H., & Lee, H. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01176-3 · Cited by 58
The Current State of Drug Discovery and a Potential Role for NMR Metabolomics
Powers, R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401803b · Cited by 54
Restructuring and innovation in pharmaceuticals and biotechs: The impact of financialisation
Gleadle, P., Parris, S., Shipman, A., & Simonetti, R. (2012) · Critical Perspectives on Accounting · doi:10.1016/j.cpa.2012.10.003 · Cited by 54
Computational protein design: a review
Coluzza, I. (2017) · Journal of Physics Condensed Matter · doi:10.1088/1361-648x/aa5c76 · Cited by 57
Huebsch, N. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.05.055 · Cited by 54
Developing Collaborative Platforms to Advance Neurotechnology and Its Translation
Borton, D. A., Dawes, H. E., Worrell, G. A., Starr, P. A., & Denison, T. (2020) · Neuron · doi:10.1016/j.neuron.2020.10.001 · Cited by 57
“…cost of drug release – in contrast to Moore’s law, originally referring to the number of transistors on a microchip doubling every two years though the cost of computers is halved, but more generally illustrating the exponential growth for technologies over time (Scannell et al., 2012) (Figure 1).”
Backgroundvan Meer, P. J. K., Graham, M. L., & Schuurman, H. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.055 · Cited by 62
“In recent years, increasing investments in research and development have not translated into more innovative drugs reaching the market (Scannell et al., 2012).”
BackgroundThe Challenges in Implementing Open Innovation in a Global Innovation-Driven Corporation
Nakagaki, P., Aber, J., & Fetterhoff, T. J. (2012) · Research-Technology Management · doi:10.5437/08956308x5504079 · Cited by 73
“Companies are increasingly acknowledging that the high cost of developing medical products is making a traditional, internally owned R&D effort insuffi cient to meet growth expectations ( Weiss and Drewry 2011 ; Philippidis 2011 ; Scannell et al. 2012 ).”
BackgroundDrug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications
Badria, F. A.-E. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.83082 · Cited by 66
Doherty, E. L., Aw, W. Y., Hickey, A. J., & Polacheck, W. J. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.624435 · Cited by 61
“Increasingly, microfluidic devices have contributed to the arsenal of experimental approaches available for understanding cardiovascular biology, and as the efficiency of drug development declines (Scannell et al., 2012), microfluidic approaches hold promise in addressing gaps in current preclinical models (Low et al.”
BackgroundManaging risks in drug discovery: reproducibility of published findings
Kannt, A., & Wieland, T. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1216-8 · Cited by 57
“Previously, drug discovery was a process-driven and technology-oriented, almost factory-like high-throughput approach starting with a gene regulated in an animal model of disease (or the parallel interrogation of many disease-related genes) via the identification and optimization of compounds to their characterization…”
BackgroundInfluentialWhite, D. T., Eroglu, A. U., Wang, G., Zhang, L., Sengupta, S., Ding, D., Rajpurohit, S. K., Walker, S. L., Ji, H., Qian, J. X., et al. (2016) · Nature Protocols · doi:10.1038/nprot.2016.142 · Cited by 53
“(1) Tecan Infinite M1000Pro microplate reader performs ARQiv scans, (2) Solo automated pipettor dispenses and serially dilutes drug stocks, (3) the COPAS XL sorts/dispenses fish into microtiter plates, (4) the barcode reader scans barcode-labeled working stock plates and drug treatment plates, (5) the Micro 10× roboti…”
MethodWali, V. B., Langdon, C. G., Held, M. A., Platt, J. T., Patwardhan, G. A., Safonov, A. M., Aktaş, B., Pusztai, L., Stern, D. F., & Hatzis, C. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1901 · Cited by 58
“The cost and time needed to develop a new chemical entity is often prohibitive (30).”
BackgroundOn the Role of Artificial Intelligence in Genomics to Enhance Precision Medicine
Álvarez-Machancoses, Ó., deAndrés‐Galiana, E. J., Cernea, A., de la Viña, J. F. S., & Fernández‐Martínez, J. L. (2020) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s205082 · Cited by 60
Drug Repurposing: A Leading Strategy for New Threats and Targets
Mishra, A. S., Vasanthan, M., & Malliappan, S. P. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00361 · Cited by 61
Harnessing QbD, Programming Languages, and Automation for Reproducible Biology
Sadowski, M. I., Grant, C., & Fell, T. S. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.11.006 · Cited by 59
“Theywarn of a loomingdanger of significantly diminishing returns on R&D expenditure in the pharmaceutical industry [12], a phenomenon somewhat facetiously known as ‘Eroom's law’.”
BackgroundAbou-Gharbia, M. A., & Childers, W. E. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401564r · Cited by 58
Concise Review: Organ Engineering: Design, Technology, and Integration
Kaushik, G. N., Leijten, J., & Khademhosseini, A. (2016) · Stem Cells · doi:10.1002/stem.2502 · Cited by 57
Mandlik, D. S., & Mandlik, S. K. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1834591 · Cited by 60
“Yet the findings reported during the 1990s from the recently launched synthetic medicines do not fulfill standards (8).”
BackgroundInnovation crisis in the pharmaceutical industry? A survey
Laermann-Nguyen, U., & Backfisch, M. (2021) · SN Business & Economics · doi:10.1007/s43546-021-00163-5 · Cited by 54
Ali, A. H., & Gittelman, M. (2016) · Research Policy · doi:10.1016/j.respol.2016.03.015 · Cited by 59
Landers, M., Dorsey, R. E., & Saria, S. (2021) · Digital Biomarkers · doi:10.1159/000517885 · Cited by 53
“It has been hypothesized that the reason for the increasing number of late-stage failures may be due to a limitation in how traditional endpoints can represent changes in the disease state [55, 56].”
BackgroundAttack or Defend? The Role of Institutional Context on Patent Litigation Strategies
Rudy, B. C., & Black, S. L. (2015) · Journal of Management · doi:10.1177/0149206315605168 · Cited by 56
Mimicking the Kidney: A Key Role in Organ-on-Chip Development
Paoli, R., & Samitier, J. (2016) · Micromachines · doi:10.3390/mi7070126 · Cited by 57
“The number of new drugs brought to market by the global bio-technology and pharmaceutical industries per billion US dollars of R&D investment has declined steadily in this period [1,3].”
BackgroundRobinson, J. R., Denny, J. C., Roden, D. M., & Driest, S. L. V. (2017) · Clinical and Translational Science · doi:10.1111/cts.12522 · Cited by 53
Andersen, J. R., Byrjalsen, I., Bihlet, A. R., Kalakou, F., Hoeck, H. C., Hansen, G., Hansen, H. B., Karsdal, M. A., & Riis, B. J. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12531 · Cited by 51
Vicini, P., Fields, O., Lai, E., Litwack, E. D., Martin, A., Morgan, T., Pacanowski, M., Papaluca, M., Perez, O. D., Ringel, M. S., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.293 · Cited by 52
Obstacles and opportunities in Chinese pharmaceutical innovation
Ni, J., Zhao, J., Ung, C. O. L., Yuanjia, H., Hu, H., & Wang, Y. (2017) · Globalization and Health · doi:10.1186/s12992-017-0244-6 · Cited by 50
“In terms of dramatically increasing R&D (Research and Development) expenditures and relatively decreasing approvals of new drugs during recent past, the decline in R&D efficiency has been the central issue of discussing global pharmaceutical innovation [1, 2].”
BackgroundMolecular mechanism matters: Benefits of mechanistic computational models for drug development
Clegg, L. E., & Gabhann, F. M. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.002 · Cited by 50
Shen, J. X., Youhanna, S. C., Shafagh, R. Z., Kele, J., & Lauschke, V. M. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00245 · Cited by 51
Lopes, M. R., Costigliola, A., Pinto, R. M. A., Vieira, S. M., & Sousa, J. M. C. (2019) · International Journal of Production Research · doi:10.1080/00207543.2019.1683250 · Cited by 49
Foley, T. L., Burchett, W., Chen, Q., Flanagan, M. E., Kapinos, B., Li, X.-Y., Montgomery, J. I., Ratnayake, A. S., Zhu, H., & Peakman, M. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220979589 · Cited by 52
CETSA: A Target Engagement Assay with Potential to Transform Drug Discovery
Jensen, A. J., Molina, D. M., & Lundbäck, T. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.50 · Cited by 49
Theoretical and Biological Evaluation of the Link between Low Exercise Capacity and Disease Risk
Koch, L. G., & Britton, S. L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029868 · Cited by 54
““Eroom’s law” (Moore’s spelled backward; Scannell et al. 2012) is the observation that drug discovery is becoming slower and more expensive over time, a trend first observed in the 1980s (Scannell et al.”
BackgroundInfluentialRadiolabelling small and biomolecules for tracking and monitoring
Edelmann, M. R. (2022) · RSC Advances · doi:10.1039/d2ra06236d · Cited by 56
Small Molecule Screening in Human Induced Pluripotent Stem Cell-derived Terminal Cell Types
Engle, S. J., & Vincent, F. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r113.529156 · Cited by 55
A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor
Licciardello, M. P., Ringler, A., Markt, P., Klepsch, F., Lardeau, C.-H., Sdelci, S., Schirghuber, E., Müller, A. C., Caldera, M., Wagner, A., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2382 · Cited by 54
Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker Based Approaches
Maciejko, L., Smalley, M., & Goldman, A. J. (2017) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.1000350 · Cited by 53
“Interestingly, the FDA-approval of existing therapies for new indications is common, with the repurposing of thalidomide to treat multiple myeloma being a notable example [25,26].”
BackgroundPerspectives on new strategies for the identification and development of insecticide targets
Swale, D. R. (2019) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2019.07.001 · Cited by 49
Seo, S., Kim, Y., Han, H., Son, W., Hong, Z.-Y., Sohn, I., Shim, J., & Hwang, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670670 · Cited by 52
“This phenomenon happens despite significant improvements at all stages of the drug development pipeline (Scannell et al., 2012).”
BackgroundSchuhmacher, A., Hinder, M., Brief, E., Gassmann, O., & Hartl, D. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104291 · Cited by 64
Precision Medicine, Cardiovascular Disease and Hunting Elephants
Joyner, M. J. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.02.004 · Cited by 47
Barral, S., & Kurian, M. A. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00078 · Cited by 52
“…et al., 2010; Hu et al., 2016); serotonergic neurons (Erceg et al., 2008); caudal neurons (Kirkeby et al., 2012); cerebellar neurons (Erceg et al., 2010); astrocytes (Emdad et al., 2012; Juopperi Frontiers in Molecular Neuroscience | www.frontiersin.org 2 September 2016 | Volume 9 | Article 78”
Background3D Miniaturization of Human Organs for Drug Discovery
Park, J., Wetzel, I., Dréau, D., & Cho, H. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700551 · Cited by 48
Griffen, E., Dossetter, A. G., Leach, A. G., & Montague, S. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.03.011 · Cited by 54
Learning to shield – Policy learning in socio-technical transitions
Boon, W., & Bakker, S. (2015) · Environmental Innovation and Societal Transitions · doi:10.1016/j.eist.2015.06.003 · Cited by 51
Financing Biomedical Innovation
Lo, A. W., & Thakor, R. T. (2022) · Annual Review of Financial Economics · doi:10.1146/annurev-financial-031721-081537 · Cited by 53
“This trend of increasing development costs over time was laid out starkly by Scannell et al. (2012), who demonstrated the declining R&D efficiency of the industry by showing how $1 billion (inflation-adjusted) of R&D spending could produce dozens of drugs in the 1950s, but by 2010 was not…”
BackgroundENPP1 in Blood and Bone: Skeletal and Soft Tissue Diseases Induced by ENPP1 Deficiency
Ferreira, C. R., Carpenter, T. O., & Braddock, D. T. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-121126 · Cited by 50
“…documented crisis in drug development, perhaps best described by Eroom’s law, which states that the number of new drugs approved per billion US dollars spent on R&D has halved roughly every 9 years since 1950, falling approximately 80-fold in inflation-adjusted terms between 1950 and 2010 (111).”
BackgroundNext-Generation Phenotypic Screening
Warchal, S. J., Unciti‐Broceta, A., & Carragher, N. O. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0025 · Cited by 50
Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics
Pulley, J. M., Shirey-Rice, J. K., Lavieri, R. R., Jerome, R. N., Zaleski, N. M., Aronoff, D. M., Bastarache, L. A., Niu, X., Holroyd, K. J., Roden, D. M., et al. (2017) · Assay and Drug Development Technologies · doi:10.1089/adt.2016.772 · Cited by 47
“A New Approach That Is Simultaneously In Vivo and In Silico It is widely known that many, but not all, existing in vitro and preclinical animal models of disease are extremely poor predictors of human biology.(21) A better way to predict drug effects in humans, in terms of both efficacy and potential adverse effects,…”
Jaradat, N. A., Al-Lahham, S., Zaid, A. N., Hussein, F., Issa, L., Abualhasan, M., Hawash, M., Yahya, A., Shehadi, O., Omair, R., et al. (2019) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2019.100933 · Cited by 46
“…chemical medications do not meet the expectations of patients, pharmaceutical companies or global health organizations, as evidenced by decreasing numbers of novel medications reaching the pharmaceutical market and unexpected harmful side effects, contraindications and drug-drug interactions [4–6].”
BackgroundPharmaceutical drug development: high drug prices and the hidden role of public funding
Annett, S. (2020) · Biologia Futura · doi:10.1007/s42977-020-00025-5 · Cited by 46
Sahoo, J. P., Behera, L., Praveena, J., Sawant, S., Mishra, A., Sharma, S. S., Ghosh, L., Mishra, A. P., Sahoo, A. R., Pradhan, P., et al. (2021) · American Journal of Plant Sciences · doi:10.4236/ajps.2021.123030 · Cited by 45
“The stimulation assay of neuraminidase demonstrates that five active derivatives of the curcumin additive reduced the activation of H1N1 induced neuraminidase in H1N1 infected lung epithelial cells [85].”
BackgroundMeasuring the effectiveness and impact of an open innovation platform
Carroll, G. P., Srivastava, S., Volini, A. S., Piñeiro-Núñez, M. M., & Vetman, T. N. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.009 · Cited by 46
Metadata
- Authors
- Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B.
- Corresponding author
- Scannell, Jack W.
- ORCID
- Scannell, Jack W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-03
- Volume
- 11
- Issue
- 3
- Pages
- 191-200
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2028279608
- Cited by
- 1,981
- References
- 85
- Citations by year
- 2026: 135 · 2025: 123 · 2024: 144 · 2023: 126 · 2022: 141 · 2021: 173 · 2020: 178 · 2019: 144 · 2018: 138 · 2017: 133 · 2016: 155 · 2015: 136 · 2014: 108 · 2013: 103 · 2012: 41
- FWCI
- 47.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- new drug approvals, drug approval rates, drug development costs, regulatory policy, drug regulation, basic research
- MeSH terms
- Animals, Drug Industry, Pharmaceutical Preparations, Humans, Research, Drug Delivery Systems, Efficiency, Organizational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.